NRXP
NRx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.42
−0.29%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.6x
Market Cap
$148.07M
MomentumView details →
1D Return
−0.29%
YTD Return
+26.75%
RSI (14)
47.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.6x
Market Cap
$148.07M
RSI (14)
47.4
MomentumView details →
1D Return
−0.29%
YTD Return
+26.75%
SummaryUpdated Jun 1, 2026
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Wilmington, Delaware. The company went public in December 2017 and focuses on developing novel therapeutics for central nervous system disorders, particularly targeting the treatment of suicidal depression and bipolar depression. NRx has evolved from a pure research and development organization into a company pursuing a dual strategy of drug development and clinical service delivery through its subsidiary Hope Therapeutics.
Similar companies
Latest newsMore news →
NRx Pharmaceuticals completed the first-cycle FDA review of its ANDA for preservative-free ketamine with no drug-related major deficiencies, and submitted the sole remaining manufacturer's attestation on the vial to the FDA.18d agoNRx Pharmaceuticals, Inc. reported a Q2 2026 loss of $0.18 per share, missing the Zacks Consensus Estimate of a loss of $0.09, and compared to a loss of $0.98 per share a year ago.21d agoNRx Pharmaceuticals completed the first-cycle FDA review of its abbreviated new drug application for preservative-free ketamine, with one remaining issue related to the product's vial connector.25d ago